SNX vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about TD SYNNEX Corporation (SNX) and Novo Nordisk A/S (NVO).

Performance

SNX vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TD SYNNEX Corporation (SNX) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

SNX vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SNX TD SYNNEX Corporation	24.40%	29.82%	10.55%	15.25%	-16.11%	41.48%	26.81%	61.74%	-39.71%	13.33%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Fundamentals

Market Cap SNX : $14.94B NVO : $162.26B
EPS SNX : $12.06 NVO : $22.15
PE Ratio SNX : 15.45 NVO : 1.65
PEG Ratio SNX : 1.19 NVO : 0.07
PS Ratio SNX : 0.23 NVO : 0.55
PB Ratio SNX : 1.70 NVO : 0.84
Total Revenue (TTM) SNX : $65.14B NVO : $297.20B
Gross Profit (TTM) SNX : $4.43B NVO : $240.66B
EBITDA (TTM) SNX : $1.91B NVO : $153.18B

Returns By Period

In the year-to-date period, SNX achieves a 24.40% return, which is significantly higher than NVO's -25.80% return. Over the past 10 years, SNX has outperformed NVO with an annualized return of 16.25%, while NVO has yielded a comparatively lower 5.04% annualized return.

SNX

• 1D: 10.42%
• 1M: 18.54%
• YTD: 24.40%
• 6M: 14.01%
• 1Y: 81.82%
• 3Y*: 26.14%
• 5Y*: 11.15%
• 10Y*: 16.25%

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SNX vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNX

SNX Risk / Return Rank: 94
SNX Sharpe Ratio Rank: 94
SNX Sortino Ratio Rank: 94
SNX Omega Ratio Rank: 93
SNX Calmar Ratio Rank: 95
SNX Martin Ratio Rank: 93

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNX vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TD SYNNEX Corporation (SNX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SNX	NVO	Difference
Sharpe ratio Return per unit of total volatility	2.59	-0.81	+3.40
Sortino ratio Return per unit of downside risk	3.43	-0.99	+4.43
Omega ratio Gain probability vs. loss probability	1.46	0.86	+0.60
Calmar ratio Return relative to maximum drawdown	5.84	-0.82	+6.66
Martin ratio Return relative to average drawdown	14.24	-1.41	+15.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SNX vs. NVO - Sharpe Ratio Comparison

The current SNX Sharpe Ratio is 2.59, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of SNX and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SNX	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.59	-0.81	+3.40
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.38	0.10	+0.28
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.47	0.16	+0.32
Sharpe Ratio (All Time) Calculated using the full available price history	0.45	0.46	-0.01

Correlation

The correlation between SNX and NVO is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SNX vs. NVO - Dividend Comparison

SNX's dividend yield for the trailing twelve months is around 0.97%, less than NVO's 4.94% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SNX TD SYNNEX Corporation	0.97%	1.17%	1.36%	1.30%	1.27%	0.70%	0.25%	1.16%	1.73%	0.77%	0.70%	0.64%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

SNX vs. NVO - Drawdown Comparison

The maximum SNX drawdown since its inception was -67.27%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for SNX and NVO.

Drawdown Indicators

	SNX	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-67.27%	-74.70%	+7.43%
Max Drawdown (1Y) Largest decline over 1 year	-13.97%	-55.03%	+41.06%
Max Drawdown (5Y) Largest decline over 5 years	-36.52%	-74.70%	+38.18%
Max Drawdown (10Y) Largest decline over 10 years	-55.94%	-74.70%	+18.76%
Current Drawdown Current decline from peak	0.00%	-73.49%	+73.49%
Average Drawdown Average peak-to-trough decline	-15.47%	-17.56%	+2.09%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.73%	31.83%	-26.10%

Volatility

SNX vs. NVO - Volatility Comparison

TD SYNNEX Corporation (SNX) has a higher volatility of 13.65% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that SNX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SNX	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.65%	9.39%	+4.26%
Volatility (6M) Calculated over the trailing 6-month period	22.73%	38.79%	-16.06%
Volatility (1Y) Calculated over the trailing 1-year period	31.79%	54.16%	-22.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	29.27%	37.82%	-8.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.41%	32.28%	+2.13%

Financials

SNX vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between TD SYNNEX Corporation and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SNX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, TD SYNNEX Corporation reported a gross profit of 1.25B and revenue of 17.16B. Therefore, the gross margin over that period was 7.3%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

SNX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, TD SYNNEX Corporation reported an operating income of 489.36M and revenue of 17.16B, resulting in an operating margin of 2.9%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

SNX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, TD SYNNEX Corporation reported a net income of 326.92M and revenue of 17.16B, resulting in a net margin of 1.9%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.